Exhibit 99.4

QUINTILES UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

The following unaudited pro forma condensed combined financial statements give effect to the merger in which IMS Health merged with and into Quintiles in a “merger of equals.” The Unaudited Pro Forma Condensed Combined Balance Sheet is presented as if the merger had occurred on June 30, 2016. The Unaudited Pro Forma Condensed Combined Statements of Income for the six months ended June 30, 2016 and the year ended December 31, 2015 are presented as if the merger had occurred on January 1, 2015, the beginning of the earliest period presented. The unaudited pro forma financial information is based on the historical consolidated financial statements of Quintiles and IMS Health, and the assumptions and adjustments set forth in the accompanying explanatory notes.

The unaudited pro forma financial information for the merger has been developed from and should be read in conjunction with the Quintiles and IMS Health unaudited interim condensed consolidated financial statements contained in the Quintiles and IMS Health Quarterly Reports on Form 10-Q for the quarterly period ended June 30, 2016, respectively, and the Quintiles audited consolidated financial statements contained in the Quintiles Annual Report on Form 10-K for the year ended December 31, 2015 and the IMS Health audited consolidated financial statements contained in the IMS Health Annual Report on Form 10-K for the year ended December 31, 2015. For purposes of developing the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2016, the acquired IMS Health assets, including identifiable intangible assets, and liabilities assumed have been recorded at their estimated fair values with the excess purchase price assigned to goodwill. The estimated fair values assigned in this unaudited pro forma financial information are preliminary and represent Quintiles’ current best estimate of fair value and are subject to revision. The unaudited pro forma financial information is provided for informational purposes only and is based on available information and assumptions that Quintiles believes are reasonable. It does not purport to represent what the actual consolidated results of operations or the consolidated financial position of the Surviving Corporation would have been had the merger occurred on the dates indicated, nor is it necessarily indicative of future consolidated results of operations or consolidated financial position. The actual financial position and results of operations will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified and changes in operating results following the date of the pro forma financial information.

Upon closing of the merger, each share of IMS Health common stock was converted into 0.3840 of a share of Surviving Corporation common stock. For purposes of this unaudited pro forma financial information, giving effect to the exchange ratio described above, the estimated aggregate consideration to complete the merger would have been $10.3 billion based upon a per share price of $79.70, the closing price of Quintiles common stock on September 27, 2016 and 329 million shares of IMS Health common stock outstanding as of June 30, 2016. The purchase price also includes the estimated fair value of $265 million for vested (based on a graded vesting attribution model) IMS Health equity awards that will be issued in respect of the equity awards held by employees of IMS Health that will be exchanged for Surviving Corporation equity awards. The accounting standards require that the consideration transferred be measured at the date the merger is completed at the then-current market price. This requirement will likely result in a total consideration that is different from the amount presented in this unaudited pro forma financial information. Based on the 329 million shares of IMS Health common stock outstanding as of June 30, 2016 and the exchange ratio, each dollar increase (decrease) in the per share price of the Quintiles common stock will result in an $126 million increase (decrease) in the total consideration for the merger, substantially all of which Quintiles expects would be recorded as an increase (decrease) in the amount of goodwill recorded in the merger. The number of outstanding shares of IMS Health common stock will change prior to the closing of the merger due to transactions in the normal course of business, including the vesting and/or exercise of outstanding IMS Health equity awards. This change is not expected to have a material effect on this unaudited pro forma financial information.

1

Unaudited Pro Forma Condensed Combined Balance Sheet

As of June 30, 2016

(in millions)

See accompanying notes to unaudited pro forma condensed combined financial information.

2

Unaudited Pro Forma Condensed Combined Statement of Income

For the Six Months Ended June 30, 2016

(in millions, except per share data)

See accompanying notes to unaudited pro forma condensed combined financial information.

3

Unaudited Pro Forma Condensed Combined Statement of Income

For the Year Ended December 31, 2015

(in millions, except per share data)

See accompanying notes to unaudited pro forma condensed combined financial information.

4

Notes to Unaudited Pro Forma Condensed Combined Financial Information

1. Description of the Merger

On October 3, 2016, Quintiles and IMS Health completed a “merger of equals” in which IMS Health merged with and into Quintiles with Quintiles continuing as the Surviving Corporation and the separate corporate existence of IMS Health ceasing. Upon completion of the merger, each share of IMS Health common stock outstanding immediately before the merger was converted into the right to receive 0.3840 of a share of Surviving Corporation common stock.

2. Basis of Presentation

The accompanying unaudited pro forma condensed combined financial statements give effect to the merger in which IMS Health merged with and into Quintiles. The unaudited pro forma financial information is based on the historical consolidated financial statements of Quintiles and IMS Health, and the assumptions and adjustments set forth in these notes. The unaudited pro forma financial information is provided for informational purposes only and is based on available information and assumptions that Quintiles believes are reasonable. It does not purport to represent what the actual consolidated results of operations or the consolidated financial position of the Surviving Corporation would have been had the merger occurred on the dates indicated, nor is it necessarily indicative of future consolidated results of operations or consolidated financial position. The actual financial position and results of operations will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified and changes in operating results following the date of the pro forma financial information.

On April 1, 2015, IMS Health completed the acquisition of certain client relationship management and strategic data businesses of Cegedim, SA at a price of €413 million (or $445 million). Accordingly, the acquired assets and liabilities are already reflected in the unaudited pro forma balance sheet. Amounts related to the pro forma statement of income for the period prior to the acquisition were not material and are not presented in the pro forma statements of income.

Merger-related pro forma adjustments are included only to the extent they are (i) directly attributable to the merger, (ii) factually supportable and (iii) with respect to the statements of income, expected to have a continuing impact on the combined results. The accompanying unaudited pro forma condensed combined financial information is presented for informational purposes only and is based on available information and assumptions that Quintiles believes are reasonable.

The unaudited pro forma condensed combined financial information does not reflect any cost savings from operating efficiencies or revenue synergies that could result from the merger.

The merger will be accounted for using the acquisition method of accounting with Quintiles considered the accounting and legal acquirer. The unaudited pro forma financial information reflects the preliminary assessment of fair values and useful lives assigned to the assets acquired and liabilities assumed. Fair value estimates were determined based on preliminary discussions between Quintiles and IMS Health, due diligence efforts and information available in public filings. The detailed valuation studies necessary to arrive at the required estimates of the fair values for the IMS Health assets acquired and liabilities assumed have not been completed. Significant assets and liabilities that are subject to preparation of valuation studies to determine appropriate fair value adjustments include property and equipment, identifiable intangible assets, unearned income and debt obligations. Changes to the fair values of these assets and liabilities will also result in changes to goodwill and deferred income tax liabilities, which could be material.

5

The Unaudited Pro Forma Condensed Combined Balance Sheet is presented as if the merger had occurred on June 30, 2016. The Unaudited Pro Forma Condensed Combined Statements of Income for the six months ended June 30, 2016 and the year ended December 31, 2015 are presented as if the merger had occurred on January 1, 2015, the beginning of the earliest period presented.

3. Preliminary Purchase Consideration

The fair value of the merger consideration, or the purchase price, in the unaudited pro forma financial information is estimated to be approximately $10.3 billion. This amount was derived based on the 329 million shares of IMS common stock outstanding on June 30, 2016, the exchange ratio and a per share price of $79.70, which represents the closing price of Quintiles common stock on September 27, 2016. The actual number of shares of Surviving Corporation common stock issued to IMS Health stockholders upon closing of the merger will be based on the actual number of shares of IMS Health common stock outstanding when the merger closes, and the valuation of those shares will be based on the per share price of Quintiles common stock at that time. IMS Health equity awards held by current employees and certain members of the IMS Health board of directors will be converted into Surviving Corporation equity awards after giving effect to the exchange ratio. The terms of these awards, including vesting provisions, will be substantially consistent to those of the historical IMS Health equity awards. The fair value of vested IMS Health equity awards will be considered part of the purchase price. Accordingly, the purchase price includes estimated fair values for IMS Health equity awards of $265 million.

The following table presents the preliminary purchase price as if the merger had closed on June 30, 2016 (in millions, except per share data):

The following table presents the preliminary allocation of purchase price to the assets to be acquired and liabilities to be assumed in the merger (in millions):

6

Upon completion of the fair value assessment following the merger, Quintiles anticipates the finalized fair values of the net assets acquired will differ from the preliminary assessment outlined above. Generally, changes to the initial estimates of the fair value of the assets acquired and liabilities assumed within a one-year measurement period from the acquisition date will be recorded as adjustments to those assets and liabilities and residual amounts will be allocated to goodwill, which could be material.

4. Merger-Related Pro Forma Adjustments

The unaudited pro forma financial information reflects the following adjustments related to the merger:

The following tables summarizes information about the other identifiable intangible assets (in millions, except useful life information):

The client relationships fair value was estimated using the excess earnings approach which is a hybrid of the income-based and cost-based methodologies and includes an estimate of how long the client will remain a client following the merger which was based upon IMS Health’s historical client attrition rates and a discount rate reflecting the risks inherent in the excess earnings approach. The amortization adjustment for the client relationships asset reflects an accelerated recognition methodology and is based on the expected net cash flows from the acquired IMS Health clients.

The product trademarks and the trade name fair values were estimated using an income-based methodology referred to as the relief-from-royalty method. This method makes use of market participant assumptions regarding the estimated future use of these assets, the hypothetical royalty payments that a market participant would be required to pay if it did not already own these assets, and a discount rate reflecting the risks inherent in the income generation of these assets. The trade name is an indefinite-lived intangible asset and will not be amortized but evaluated for impairment annually, or more frequently if events or circumstances indicate an impairment. The amortization adjustment for the product trademarks asset reflects an accelerated recognition methodology which is based on the hypothetical net cash flows from the acquired product trademarks.

The software fair value was estimated using an income-based methodology referred to as the relief-from-royalty method. This method makes use of market participant assumptions regarding the estimated future

7

use of these assets, the hypothetical royalty payments that a market participant would be required to pay if it did not already own these assets, and a discount rate reflecting the risks inherent in the income generation of these assets. The amortization adjustment for the software asset reflects an accelerated recognition methodology which is based on the hypothetical net cash flows from the software.

The databases fair value was estimated using a cost-based methodology based on the historical costs of obtaining the databases and processing costs, estimates of the useful life of the databases, and other relevant characteristics. The amortization adjustment for the databases is on a straight-line basis over the estimated useful life.

The amortization of the software and databases intangible assets are reflected in costs of revenues. The amortization of client relationships and product trademarks are reflected in selling, general and administrative expenses. For the six months ended June 30, 2016, amortization expense in costs of revenue was $192 million and amortization expense in selling, general and administrative expenses was $188 million. For the year ended December 31, 2015, amortization expense in costs of revenues was $393 million and amortization expense in selling, general and administrative expenses was $225 million. Costs of revenue and selling, general and administrative expenses were further adjusted by $18 million and $131 million, respectively, for the six months ended June 30, 2016, and by $35 million and $263 million, respectively, for the year ended December 31, 2015, to eliminate the amortization of intangible assets recorded in IMS Health’s historical Statements of Comprehensive Income (Loss).

8

9